Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SGNC Sanguine Corp. Info Thread -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (67)	6/30/1998 2:27:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 100

PATHOLOGY JOURNAL NOTES NO LUNG SIDE EFFECTS Bruch LA, Flint A, Hirschl RB. Pulmonary pathology of patients treated with partial liquid ventilation, Modern Pathology, 10:463-468, 1997. "Conclusion: Perfluorocarbon liquid ventilation in patients with adult and neonatal respiratory distress syndromes is not associated with unique pathologic findings in the human lung. " ...THEY ARE SAYING THAT THERE ARE NO SERIOUS LUNG SIDE EFFECTS WITH PFC'S. Pulmonary Pathology of Patients Treated with Perfluorocarbon Partial Liquid Ventilation L.A. Bruch, A. Flint, R Hirschl, University of Michigan Medical Center Background: Initial trials of partial liquid ventilation (PLV, gas ventilation of perfluorocarbon-filled lungs) are underway in patients with severe respiratory failure. We report the first study of the effects of perfluorocarbon upon the lung. Design: Necropsies were conducted in 12 patients (10 adults and 2 neonates with mean adult age of 39 years) managed with PLV (average number of doses = 4). Nine of twelve patients required extracorporeal life support (ECLS). 8 patients had pneumonia, 2 trauma/capillary leak syndrome, 1 congenital diaphragmatic hernia, and 1 alveolar capillary dysplasia. Twelve adult patients (mean age 39 years) with adult respiratory distress syndrome requiring ECLS served as a control. Pathologic findings were evaluated in both groups. Results: Lung weights in adult patients of both groups were elevated (mean weight PFC right lung 1295ñ451 gm, left lung 1061ñ415 gm; control right lung 994ñ259 gm, left lung 993ñ224 gm). There was no significant difference between the two groups (right lung, P=0.064 left lung P=0.631). There was no difference in lung weights in patients receiving liquid ventilation on ECLS and those not requiring ECLS. Frequent gross findings included focal consolidation, patchy hemorrhage and glassy cut surfaces. The histologic findings were similar in both groups. Diffuse alveolar damage, proliferative phase, or mixed proliferative and exudative phases, was seen in all 12 of the study patients, 10 of 12 control patients had diffuse alveolar damage (5 had proliferative phase only, 1 had mixed proliferative and exudative phases, and 4 exudative phase only). Two other patients had extensive parenchymal necrosis. Other frequent findings were intra-alveolar hemorrhage, numerous intra-alveolar macrophages, and organization of exudate. Conclusion: Perfluorocarbon liquid ventilation in patients with adult and neonatal respiratory distress syndromes is not associated with unique pathologic findings in the human lung.